Skip to main content

Effects of Bifidobacterium animalis subsp. lactis HN019 on ligature-induced periodontitis in rats with experimental rheumatoid arthritis.

  • 2020-02-19
  • Beneficial Microbes 11(1)
    • R. S. Cardoso
    • M. Messora
    • P. Silva
    • L. F. Oliveira
    • C. Leite-Panissi
    • S. Salvador
    • R. Casarin
    • A. B. Novaes
    • D. Palioto
    • F. Furlaneto

Abstract

The purpose of this study was to evaluate the effects of systemic administration of the probiotic Bifidobacterium animalis subsp. lactis HN019 (HN019) on ligature-induced periodontitis in rats with experimental rheumatoid arthritis (RA). 28 rats were divided into four groups (n=7): RA (rheumatoid arthritis), RA/PROB (probiotic), RA/EP (experimental periodontitis) and RA/EP/PROB. From day zero, HN019 was added daily to the water of the PROB groups animals until the end of the experiment. From day seven, RA was induced. On day 28, in EP groups, ligatures were positioned around mandibular first molars and remained in position for 11 days, in order to induce periodontitis. The animals were euthanised on day 39. Microtomographic, histomorphometric, immunoenzymatic and microbiological analyses were performed. Data were statistically analysed (P<0.05). Group RA/EP/PROB presented reduced alveolar bone loss, tumour necrosis factor-α and interleukin (IL)-6 levels and increased IL-17 levels when compared with group RA/EP. There were no significant differences regarding connective tissue attachment level and IL-10 levels between groups RA/EP and RA/EP/PROB. Group RA/PROB showed decreased anti-citrullinated protein antibodies levels when compared with groups RA and RA/EP. Group RA/EP/PROB presented a higher rate of aerobic/anaerobic bacteria than group RA/EP. Systemic administration of HN019 promoted a protective effect against periodontal tissue destruction, decreasing both bone loss and inflammatory mediators and increasing the proportion of bacteria compatible with periodontal health, in rats with experimental RA and EP.

Keywords: bone resorption; periodontal disease; probiotics; rheumatic diseases.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium animalis subsp. lactis HN019Increased Aerobic to Anaerobic Bacteria RatioBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Increased IL-17 LevelsBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Reduced Alveolar Bone ResorptionBeneficial
Large
Bifidobacterium animalis subsp. lactis HN019Reduced Anti-citrullinated Protein Antibodies LevelsBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Reduced Proinflammatory MediatorsBeneficial
Large
Bifidobacterium lactis HN019Elevated Interleukin-17 LevelsBeneficial
Small
Bifidobacterium lactis HN019Increased Proportion of Aerobic and Anaerobic BacteriaBeneficial
Moderate
Bifidobacterium lactis HN019No Change in Interleukin-10 LevelsNeutral
Small
Bifidobacterium lactis HN019Reduced Alveolar Bone ResorptionBeneficial
Large
Bifidobacterium lactis HN019Reduced Anti-citrullinated Protein Antibodies LevelsBeneficial
Moderate
Bifidobacterium lactis HN019Reduced Interleukin-6 LevelsBeneficial
Moderate
Bifidobacterium lactis HN019Reduced Tumor Necrosis Factor AlphaBeneficial
Moderate
Bifidobacterium lactis HN019Stabilized Connective Tissue Attachment LevelsNeutral
Small

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.